Niche Quality Controls Target labs in clinical and forensic toxicology that require high-quality QC materials across urine, serum, blood, oral fluid, and starting matrices, highlighting UTAK's customized control solutions to support new method development.

Xylazine Control Opportunity Capitalize on the October 2024 development of Xylazine control to address the growing opioid epidemic gap; position UTAK as a supplier of specialized controls for emerging toxicology testing panels.

Small-to-Mid Market Focus Leverage the company size (11-50 employees) to appeal to mid-sized reference laboratories and regional labs seeking personalized, responsive QC material partnerships with faster turnaround and tailored solutions.

Compliance and Safety Messaging Emphasize health and safety safeguards through superior testing control materials to differentiate from larger competitors, appealing to labs prioritizing accuracy and regulatory compliance in quality assurance programs.

Digital Engagement Utilize existing tech stack and digital channels (LinkedIn insights, Mailchimp campaigns, Zendesk chat) to nurture leads, promote new controls, and drive pilot opportunities for labs evaluating new QC materials and method development.